Organigram Global (STU:0OG) Beneish M-Score: -2.39 (As of Jun. 26, 2026)


STU:0OG Organigram Global Inc STU:0OG
60 GF Score
Price €0.82
GF Value €1.46
Valuation Possible Value Trap
! 1 Warning Sign
View Full Analysis

What is Organigram Global Beneish M-Score?

Organigram Global STU:0OG -0.85% 60 Beneish M-Score is -2.39 as of Jun. 26, 2026. GuruFocus rates STU:0OG with a GF Score™ of 60/100 and a GF Value™ of €1.46 (Possible Value Trap). The stock has 1 warning sign investors should review. Among 911 Drug Manufacturers companies, Organigram Global ranks worse than 58.18% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.39 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Organigram Global's Beneish M-Score or its related term are showing as below:

STU:0OG' s Beneish M-Score Range Over the Past 10 Years
Min: -7.53   Med: -2.19   Max: 75.65
Current: -2.39

During the past 13 years, the highest Beneish M-Score of Organigram Global was 75.65. The lowest was -7.53. And the median was -2.19.


Organigram Global Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Organigram Global's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Organigram Global Beneish M-Score Chart

Organigram Global Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Sep24 Sep25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.15 -1.34 -2.91 -3.04 -1.58

Organigram Global Quarterly Data
Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.51 -1.82 -1.58 -2.10 -2.39

STU:0OG vs ZTS: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Organigram Global's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Organigram Global Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Organigram Global's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Organigram Global's Beneish M-Score falls into.


STU:0OG
60GF Score
Organigram Global Inc STU:0OG
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Organigram Global Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Organigram Global for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.784+0.528 * 0.9198+0.404 * 0.9732+0.892 * 1.3329+0.115 * 0.7842
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9704+4.679 * 0.016725-0.327 * 1.1811
=-2.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was €33.7 Mil.
Revenue was 37.698 + 39.334 + 49.307 + 44.905 = €171.2 Mil.
Gross Profit was 10.344 + 14.433 + 19.608 + 16.585 = €61.0 Mil.
Total Current Assets was €157.7 Mil.
Total Assets was €328.7 Mil.
Property, Plant and Equipment(Net PPE) was €76.2 Mil.
Depreciation, Depletion and Amortization(DDA) was €12.3 Mil.
Selling, General, & Admin. Expense(SGA) was €58.1 Mil.
Total Current Liabilities was €56.0 Mil.
Long-Term Debt & Capital Lease Obligation was €4.6 Mil.
Net Income was -0.581 + 12.362 + -23.381 + -3.992 = €-15.6 Mil.
Non Operating Income was 5.593 + 14.478 + -26.43 + -8.939 = €-15.3 Mil.
Cash Flow from Operations was -4.262 + -9.913 + -0.894 + 9.278 = €-5.8 Mil.
Total Receivables was €32.2 Mil.
Revenue was 42.268 + 28.643 + 29.73 + 27.833 = €128.5 Mil.
Gross Profit was 11.867 + 9.26 + 11.451 + 9.495 = €42.1 Mil.
Total Current Assets was €166.6 Mil.
Total Assets was €346.6 Mil.
Property, Plant and Equipment(Net PPE) was €77.3 Mil.
Depreciation, Depletion and Amortization(DDA) was €9.5 Mil.
Selling, General, & Admin. Expense(SGA) was €44.9 Mil.
Total Current Liabilities was €48.7 Mil.
Long-Term Debt & Capital Lease Obligation was €5.3 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(33.659 / 171.244) / (32.208 / 128.474)
=0.196556 / 0.250697
=0.784

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(42.073 / 128.474) / (60.97 / 171.244)
=0.327483 / 0.356042
=0.9198

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (157.671 + 76.184) / 328.67) / (1 - (166.561 + 77.284) / 346.587)
=0.288481 / 0.296439
=0.9732

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=171.244 / 128.474
=1.3329

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(9.492 / (9.492 + 77.284)) / (12.349 / (12.349 + 76.184))
=0.109385 / 0.139485
=0.7842

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(58.094 / 171.244) / (44.916 / 128.474)
=0.339247 / 0.349612
=0.9704

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((4.565 + 55.951) / 328.67) / ((5.304 + 48.726) / 346.587)
=0.184124 / 0.155892
=1.1811

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-15.592 - -15.298 - -5.791) / 328.67
=0.016725

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Organigram Global has a M-score of -2.44 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.39 mean?
Organigram Global (STU:0OG) has a Beneish M-Score of -2.39 as of Jun. 26, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Organigram Global and its competitors. According to the industry distribution chart, Organigram Global ranks #530 out of 911 companies in the Drug Manufacturers industry, placing it in the top 58.2%.
Is Organigram Global's Beneish M-Score too high?
Organigram Global's current Beneish M-Score is -2.39. Based on the distribution chart, Organigram Global ranks #530 out of 911 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Organigram Global has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Organigram Global's Beneish M-Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Organigram Global ranks #530 out of 911 companies for Beneish M-Score. This places Organigram Global in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Organigram Global and its competitors. Organigram Global's current Beneish M-Score is -2.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Organigram Global stock overvalued right now?
Based on GuruFocus' analysis, Organigram Global (STU:0OG) is currently considered Possible Value Trap. The stock's GF Value™ is €1.46, compared to a current price of €0.82 — trading 44.1% below its estimated fair value. The current Beneish M-Score is -2.39. Organigram Global's overall GF Score™ is 60/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Organigram Global (STU:0OG), the current Beneish M-Score is -2.39 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Organigram Global (STU:0OG) Overvalued in 2026?

Based on GuruFocus' analysis, Organigram Global stock appears to be undervalued. The current stock price of €0.82 is trading 44.1% below its estimated GF Value™ of €1.46. GuruFocus considers Organigram Global to be Possible Value Trap.

Key valuation signals for STU:0OG:

  • Beneish M-Score: -2.39
  • GF Value™: €1.46 vs. price of €0.82 (44.1% below fair value)
  • GF Score™: 60/100 with 1 warning sign

No single metric tells the full story. See the STU:0OG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Organigram Global Business Description

Other Exchanges OGI:USAOGI:Canada
Address 145 King Street West, Suite 1400, Toronto, ON, CAN, M5H 1J8
Organigram Global Inc is a licensed cultivator of cannabis and manufacturer of cannabis-derived goods in Canada. It is is focused on producing high-quality cannabis for adult recreational consumers. It has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O' Buds, SHRED, SHRED'ems, Monjour, Tremblant Cannabis, Trailblazer, BOXHOT and DEBUNK. Organigram operates facilities in Moncton, New Brunswick and Lac-Superieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba.
60GF Score

Get the complete analysis for STU:0OG

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.82
Price
€1.46
GF Value